Drugs / KHK2455
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03915405 | Sep 2019 → Nov 2022 | urothelial carcinoma | Kyowa Kirin, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02867007 | Aug 2016 → Dec 2019 | carcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04321694 Background | — | glioblastoma | Kyowa Kirin, Inc. | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK2455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03915405 ↗ |
| Action | Inhibit | “KHK2455 is a long-acting selective IDO1 inhibitor that blocks the heme component of the IDO holoenzyme.” PMID 40536766 ↗ Jul 2025 |
| Route | Oral | “Patients received oral KHK2455 at fixed doses of 0.3, 1, 3, 10, 30, and 100 mg once daily as run-in monotherapy for 28 days (cycle 0)” PMID 40536766 ↗ Jul 2025 |
| Target | IDO1 | “KHK2455 is a long-acting selective IDO1 inhibitor that blocks the heme component of the IDO holoenzyme.” PMID 40536766 ↗ Jul 2025 |